Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:11
|
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019
    Montastruc, Jean-Louis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (01) : 201 - 208
  • [32] Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Liu, Yan-xin
    Dong, Chang-jiang
    He, Xu-cheng
    Shu, Ya-min
    Wu, Pan
    Zou, Jian
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2022, 25 : 377 - 390
  • [33] Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System
    Lin, Yuhao
    Deng, Muling
    Xu, Siqi
    Chen, Chuanben
    Ding, Jianming
    ONCOLOGY, 2025,
  • [34] Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study
    Akinola, Samuel
    da Silveira, Carolina Galli
    Corbin, Sonia
    Lavallee, Maude
    Thibault, Magalie
    Gonella, Jennifer
    Escobar Gimenes, Fernanda Raphael
    Leclerc, Jacinthe
    PHARMACEUTICAL MEDICINE, 2020, 34 (04) : 263 - 269
  • [35] Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study
    Samuel Akinola
    Carolina Galli da Silveira
    Sonia Corbin
    Maude Lavallée
    Magalie Thibault
    Jennifer Gonella
    Fernanda Raphael Escobar Gimenes
    Jacinthe Leclerc
    Pharmaceutical Medicine, 2020, 34 : 263 - 269
  • [36] Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)
    Akagi, Tomoaki
    Hamano, Hirofumi
    Miyamoto, Hirotaka
    Takeda, Tatsuaki
    Zamami, Yoshito
    Ohyama, Kaname
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (01) : 129 - 137
  • [37] Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®)
    Amandine Dernoncourt
    Sophie Liabeuf
    Youssef Bennis
    Kamel Masmoudi
    Sandra Bodeau
    Solène Laville
    Anne-Sophie Hurtel-Lemaire
    Valérie Gras-Champel
    Benjamin Batteux
    BioDrugs, 2023, 37 : 73 - 87
  • [38] Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports
    Fernandez, Silvia
    Lenoir, Camille
    Samer, Caroline
    Rollason, Victoria
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (05):
  • [39] Myositis associated with Immune Checkpoint Inhibitors: A pharmacovigilance study using the World Health Organization's adverse drug reactions database
    Ladhari, C.
    Nguyen, T.
    Maria, A.
    Palassin, P.
    Quantin, X.
    Lesage, C.
    Taieb, G.
    Ayrignac, X.
    Rullier, P.
    Lambotte, O.
    Guilpain, P.
    Hillaire-Buys, D.
    Faillie, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 103 - 103
  • [40] Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system
    Yang, Zeping
    Tang, Kejing
    Chen, Jie
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1439 - 1446